Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	CA$0.1150	0.00%	167,047
15/10/26	CA$0.1150	0.00%	15,780
14/10/26	CA$0.1150	+4.55%	130,240
13/10/26	CA$0.1100	-4.35%	33,831
09/10/26	CA$0.1150	0.00%	16,365

End-of-day quote Toronto S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1150CAD

Average target price

1.000CAD

Spread / Average Target

+769.57%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Sernova Biotherapeutics Inc

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sernova Biotherapeutics Inc

Company calendar

End-of-day quote Toronto S.E. 16/10/2026			5-day change	1st Jan Change
0.1150 ^CAD	0.00%		0.00%	-11.54%

09-11	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09-09	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI

Market Cap	43.43M 30.7M 27.29M 25.3M 23.01M 2.91B 44.13M 304M 119M 1.52B 115M 113M 4.85B	P/E 2026 *	-4.6x	P/E 2027 *	-3.83x
Enterprise Value	43.43M 30.7M 27.29M 25.3M 23.01M 2.91B 44.13M 304M 119M 1.52B 115M 113M 4.85B	EV / Sales 2026 *	-	EV / Sales 2027 *	17.4x
Free-Float	89.49%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Toronto S.E.	SVA	End-of-day quote
Toronto S.E.	SVA	Delayed
OTC Markets	SEOVF	Delayed
Boerse Muenchen	PSH0	Real-time
Deutsche Boerse AG	PSH0	Delayed
Börse Stuttgart	PSH0	Delayed
Tradegate	PSH0	Real-time
Xetra	PSH0	Delayed

09-11	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09-09	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI
06-17	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT
06-12	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
04-23	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI
03-14	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
03-05	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding	CI
12-20	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025	CI
12-19	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt	CI
11-13	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding	CI
23/09/25	Sernova Biotherapeutics Inc Appoints John L. Brooks III as Chair of the Board of Directors	CI
16/09/25	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
09/07/25	Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes	MT

Sernova Biotherapeutics Inc Stock

Stocks

SVA

CA81752F1062

Medical Equipment, Supplies & Distribution

Valuation: Sernova Biotherapeutics Inc

Chart: Sernova Biotherapeutics Inc

Latest news: Sernova Biotherapeutics Inc

Press Releases: Sernova Biotherapeutics Inc

News in other languages: Sernova Biotherapeutics Inc

Quotes and Performance

Price Extremes

Managers and Directors: Sernova Biotherapeutics Inc

Latest insider transactions

Medical Devices & Implants

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

10-05	Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial	AQ
09-25	Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference	AQ
09-12	Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.	NE
09-10	Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference	AQ
09-08	Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics	AQ

15/09/23	Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben
13/09/23	Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung
03/05/23	AstraZeneca : accord de recherche avec le canadien Sernova
03/05/23	Sernova kündigt Forschungskooperation mit dem Pharmakonzern AstraZeneca an, um neuartige potenzielle Zelltherapie-Anwendungen zu untersuchen
10/04/23	Sernova präsentiert beim 2023 Cell & Gene Meeting on the Med der Alliance for Regenerative Medicine

Current month	+9.52%
1 month	+9.52%
6 months	-37.84%
Current year	-11.54%

1 week	0.1	0.12
1 month	0.08	0.12
Current year	0.08	0.2
1 year	0.08	0.2
3 years	0.08	0.82
5 years	0.08	2.22
10 years	0.08	2.87

Manager	Title	Age	Since
Jonathan Rigby CEO	Chief Executive Officer	59	12/08/2024
Marie Kaldchibachi DFI	Director of Finance/CFO	-	01/11/2023
James Parsons DFI	Director of Finance/CFO	61	07/10/2024

Director	Title	Age	Since
Steven Sangha BRD	Director/Board Member	-	24/04/2023
Jonathan Rigby CHM	Chairman	59	02/06/2025
David Paterson BRD	Director/Board Member	-	01/09/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/7/26	SERNOVA BIOTHERAPEUTICS, INC.	Sell	Company	-115,000	0.0305%
22/5/26	John Brooks	Option	Chairman	228,912	0.0658%
22/5/26	Steven Sangha	Option	Director	260,000	0.0748%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERNOVA BIOTHERAPEUTICS INC	0.00%	0.00%	-34.29%	-84.03%	30.7M
ABBOTT LABORATORIES	+0.20%	+5.31%	-18.40%	+13.84%	181B
MEDTRONIC PLC	-0.73%	+7.09%	-1.08%	+30.13%	116B
STRYKER CORPORATION	+0.49%	+6.25%	-21.30%	+9.62%	113B
ESSILORLUXOTTICA	+3.83%	+5.50%	-50.59%	-6.11%	79.83B
CENCORA, INC.	-0.14%	+5.27%	+5.00%	+81.87%	65.06B
HOYA CORPORATION	+2.79%	+2.37%	+15.85%	+65.97%	54.35B
BECTON, DICKINSON AND COMPANY	-1.04%	+4.35%	+1.40%	-26.05%	52.23B
IDEXX LABORATORIES, INC.	+2.41%	+8.18%	-11.81%	+28.50%	44.15B
DEXCOM, INC.	-1.90%	+2.29%	+29.19%	+6.90%	32.47B
Average	+0.59%	+4.76%	-8.60%	+12.06%	73.86B
Weighted average by Cap.	+0.60%	+5.59%	-11.14%	+21.17%

	2026 *	2027 *
Net sales	-	2.5M 1.77M 1.57M 1.46M 1.32M 168M 2.54M 17.5M 6.86M 87.53M 6.63M 6.49M 279M
Net income	-11.3M -7.99M -7.1M -6.58M -5.99M -758M -11.48M -79.11M -31.02M -396M -29.98M -29.34M -1.26B	-13.9M -9.83M -8.73M -8.1M -7.37M -933M -14.12M -97.32M -38.16M -487M -36.88M -36.09M -1.55B
Net Debt	-	-